Loading
5 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Adenosquamous carcinoma of the cervix is an uncommon cervical cancer containing both gland-forming and squamous cancer cells. Like cervical adenocarcinoma it is caught less well by smear screening and does somewhat worse than squamous cancer stage for stage, but it is treated the same way, with surgery when early and chemoradiation when advanced.
The WHO classification of female genital tumours lists adenosquamous carcinoma among the HPV-associated cervical carcinomas, defined by both malignant glandular and squamous components. Cytology screening often fails to prevent adenocarcinoma; in a case-control study of 12,418 women with cervical cancer in England and Wales, being up to date with screening halved the odds of adenocarcinoma (odds ratio 0.46) and reduced advanced-stage adenocarcinoma more, and the paper treats adenosquamous carcinoma with adenocarcinoma (International Journal of Cancer 2016). In 148 patients with stage I to IVA adenocarcinoma or adenosquamous carcinoma treated with definitive radiotherapy, five-year relapse-free survival was 68 percent for non-bulky IB/IIA, 38 percent bulky IB/IIA, 49 percent IIB, 30 percent III and 0 percent IVA, inferior to squamous cell carcinoma, with distant failure common (Int J Radiat Oncol Biol Phys 2011).
How it differs from its parent: the parent page covers cervical cancer overall, three quarters squamous; adenosquamous carcinoma shares adenocarcinoma's screening blind spot and its worse radiotherapy outcomes, and its glandular component may raise the risk of ovarian and distant spread.
| Setting | Approach | Guideline |
|---|---|---|
| All stages | Treated as cervical cancer by stage: radical hysterectomy when early, cisplatin chemoradiation with brachytherapy when locally advanced, platinum with pembrolizumab or bevacizumab when recurrent. | not mapped |